Fatty Liver in Pakistani Cohort with Rheumatoid Arthritis

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2020 Jun 5

PMID 32494263

Citations 7

Authors

Abrar Ahmed Wagan

Abdul Qadir Bhutoo

Daim Khan

Abdul Raheem

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the frequency of fatty liver (non-alcoholic) disease, Framingham 10-year cardiovascular risk score in rheumatoid arthritis patients.

Methods: This study was conducted from September 1 to March 19, 2019, at Rheumatology OPD, Central Park Medical College Lahore. One hundred ninety two seropositive rheumatoid arthritis patients were recruited. Demographic details were noted, BP, BMI, smoking habits, and waist circumference were noted, then sent to radiology department for ultrasound scan of abdomen by an expert radiologist. On next day 10 ml blood was taken by phlebotomist for lipid profile and fasting blood sugar levels, after availability of results 10-years Framingham cardiovascular risk score was calculated.

Results: Females were (81.3%) mean age of (45.4) years, fatty liver was present in n=39 (20.3%). In positive cases comorbid like metabolic syndrome was present (71.8%), diabetes mellitus (33.3%), hypertension (59%) FRS score (intermediate to high in (33.3%), history of hakeem/desi medication use (51.3%), while on regression analysis all study parameters except DMARD's had significant association with fatty liver (p<0.05).

Conclusion: Nonalcoholic fatty liver disease is very widely prevalent in rheumatoid arthritis patients. As in general population, it is multifactorial in origin and needs careful monitoring and treatment.

Citing Articles

Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis.

Chen P, Hsu W, Peng C, Liao T, Chang S, Chen H Front Med (Lausanne). 2024; 11:1347268.

PMID: 38371515 PMC: 10869587. DOI: 10.3389/fmed.2024.1347268.

Increased NAFLD risk in newly diagnosed patients with RA during the first 4 years of follow-up: a nationwide, population-based cohort study.

Ho W, Chen H, Chen P, Liao T, Chang S, Chen Y BMJ Open. 2024; 14(1):e079296.

PMID: 38272552 PMC: 10824018. DOI: 10.1136/bmjopen-2023-079296.

Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis.

Zamani M, Alizadeh-Tabari S, Chitkara P, Singh S, Loomba R Clin Gastroenterol Hepatol. 2023; 21(11):2789-2796.

PMID: 36871771 PMC: 10792512. DOI: 10.1016/j.cgh.2023.02.021.

Premature Ejaculatory Dysfunction in Rheumatoid Arthritis (PED-RA Study).

Wagan A, Chandio S, Surahyo P Pak J Med Sci. 2022; 38(8):2131-2136.

PMID: 36415268 PMC: 9676567. DOI: 10.12669/pjms.38.8.5698.

Effect of glucocorticoids combined with disease modifying anti-rheumatic drugs on the improvement of symptoms in patients with rheumatoid arthritis.

Si L, Jin Y, Zhao D, Yu L, Cao H Pak J Med Sci. 2022; 38(4Part-II):976-980.

PMID: 35634625 PMC: 9121955. DOI: 10.12669/pjms.38.4.5458.

References

Hu X, Li Y, Li L, Zheng Y, Lv J, Huang S . Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. BMJ Open. 2018; 8(4):e019974. PMC: 5892783. DOI: 10.1136/bmjopen-2017-019974. View

Parkash O, Hamid S . Are we ready for a new epidemic of under recognized liver disease in South Asia especially in Pakistan? Non alcoholic fatty liver disease. J Pak Med Assoc. 2013; 63(1):95-9. View

Yamagishi K, Iso H . The criteria for metabolic syndrome and the national health screening and education system in Japan. Epidemiol Health. 2017; 39:e2017003. PMC: 5343105. DOI: 10.4178/epih.e2017003. View

Lee Y, Bae S, Song G . Meta-analysis of associations between the peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and susceptibility to nonalcoholic fatty liver disease, rheumatoid arthritis, and psoriatic arthritis. Genet Test Mol Biomarkers. 2014; 18(5):341-8. PMC: 4010165. DOI: 10.1089/gtmb.2013.0503. View

Ruderman E, Crawford J, Maier A, Liu J, Gravallese E, Weinblatt M . Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol. 1997; 36(2):210-3. DOI: 10.1093/rheumatology/36.2.210. View

van Ede A, Laan R, Blom H, De Abreu R, van de Putte L . Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998; 27(5):277-92. DOI: 10.1016/s0049-0172(98)80049-8. View

Rau R, Karger T, Herborn G, Frenzel H . Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol. 1989; 16(4):489-93. View

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P . Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015; 47(3):181-90. DOI: 10.1016/j.dld.2014.09.020. View

Sakthiswary R, Chan G, Koh E, Leong K, Thong B . Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal. 2014; 2014:823763. PMC: 4058155. DOI: 10.1155/2014/823763. View

10.

Ursini F, Russo E, Mauro D, Abenavoli L, Ammerata G, Serrao A . Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. Eur J Clin Invest. 2017; 47(10):728-735. DOI: 10.1111/eci.12798. View

11.

Quintin E, Scoazec J, Marotte H, Miossec P . Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther. 2010; 12(4):R143. PMC: 2945037. DOI: 10.1186/ar3085. View

12.

Kremer J, Galivan J, Streckfuss A, Kamen B . Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986; 29(7):832-5. DOI: 10.1002/art.1780290703. View

13.

Feagins L, Flores A, Arriens C, Park C, Crook T, Reimold A . Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015; 27(10):1154-60. PMC: 5157831. DOI: 10.1097/MEG.0000000000000421. View

14.

Selmi C, De Santis M, Gershwin M . Liver involvement in subjects with rheumatic disease. Arthritis Res Ther. 2011; 13(3):226. PMC: 3218873. DOI: 10.1186/ar3319. View

15.

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. DOI: 10.1002/hep.25762. View

16.

Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y . Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002; 12(3):183-90. DOI: 10.1097/00008571-200204000-00002. View

17.

Khov N, Sharma A, Riley T . Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(22):6821-5. PMC: 4051921. DOI: 10.3748/wjg.v20.i22.6821. View

18.

Adams L, Angulo P . Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006; 82(967):315-22. PMC: 2563793. DOI: 10.1136/pgmj.2005.042200. View

19.

Treeprasertsuk S, Leverage S, Adams L, Lindor K, St Sauver J, Angulo P . The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012; 32(6):945-50. PMC: 3348257. DOI: 10.1111/j.1478-3231.2011.02753.x. View

20.

Ranganathan P, Eisen S, Yokoyama W, McLeod H . Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?. Ann Rheum Dis. 2002; 62(1):4-9. PMC: 1754300. DOI: 10.1136/ard.62.1.4. View